Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer
详细信息 查看全文
- 作者：Satish Gupta (1) (2)
Katarzyna Jaworska-Bieniek (1) (2)
Steven A. Narod (3)
Jan Lubinski (1) (2)
Tomasz K. Wojdacz (4) (5)
Anna Jakubowska (1) - 关键词：Breast cancer risk ; BRCA1 promoter methylation ; Peripheral blood ; Methylation ; sensitive high ; resolution melting (MS ; HRM)
- 刊名：Breast Cancer Research and Treatment
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：148
- 期：3
- 页码：615-622
- 全文大小：387 KB
- 参考文献：1. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before age 40?years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83:2335-345 CrossRef
2. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretière JM, Sauvan R, Noguchi T, Birnbaum D, Sobol H (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58:1588-592
3. Iau PT, Marafie M, Ali A, Sng JH, Macmillan RD, Pinder S, Denley HE, Ellis IO, Wenzyck P, Scott N, Cross G, Blamey RW (2004) Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. Breast Cancer Res Treat 85:81-8 CrossRef
4. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-318 CrossRef
5. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-288 CrossRef
6. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029-034 CrossRef
7. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90:5-4 CrossRef
8. Mavaddat N, Barrowdale D, Andrulis I (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev 21:134-47 CrossRef
9. Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20:3254-258 CrossRef
10. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-50 CrossRef
11. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A (2000) Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21:147-51 CrossRef
12. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761-765 CrossRef
13. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-69- 作者单位：Satish Gupta (1) (2)
Katarzyna Jaworska-Bieniek (1) (2)
Steven A. Narod (3)
Jan Lubinski (1) (2)
Tomasz K. Wojdacz (4) (5)
Anna Jakubowska (1)
1. Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
2. Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland
3. Womens College Research Institute, University of Toronto, 790 Bay St, 7th Floor, Toronto, ON, M5G1N8, Canada
4. Institute of Biomedicine, University of Aarhus, ?rhus, Denmark
5. Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden- ISSN：1573-7217
- 作者单位：Satish Gupta (1) (2)
文摘
It has been proposed that methylation signatures in blood-derived DNA may correlate with cancer risk. In this study, we evaluated whether methylation of the promoter region of the BRCA1 gene detectable in DNA from peripheral blood cells is a risk factor for breast cancer, in particular for tumors with pathologic features characteristic for cancers with BRCA1 gene mutations. We conducted a case–control study of 66 breast cancer cases and 36 unaffected controls. Cases were triple-negative or of medullary histology, or both; 30 carried a constitutional BRCA1 mutation and 36 did not carry a mutation. Blood for DNA methylation analysis was taken within three months of diagnosis. Methylation of the promoter of the BRCA1 gene was measured in cases and controls using methylation-sensitive high-resolution melting (MS-HRM). A sample with any detectable level of methylation was considered to be positive. Methylation of the BRCA1 promoter was detected in 15 of 66 cases and in 2?of 36 controls (OR 5.0, p?=?0.03). Methylation was present in 15 of 36 women with breast cancer and without germline BRCA1 mutation, but in none of 30 women with breast cancer and a germline mutation (p?BRCA1 mutation (OR 12.1, p?=?0.0006). Methylation of the promoter of the BRCA1 gene detectable in peripheral blood DNA may be a marker of increased susceptibility to triple-negative or medullary breast cancer.